首頁 › 慢性淋巴性白血病 › 德克薩斯州 › Dallas
Dallas, TX 的 慢性淋巴性白血病 臨床試驗
10 項針對 慢性淋巴性白血病 的研究正在 Dallas（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中1 期
- Baylor University Medical Center, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Baylor Scott & White Health, Dallas
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
招募中1 期
- UT Southwestern Medical Center, Dallas
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
招募中2 期
- Texas Oncology - Sammons Cancer Center, Dallas
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
招募中3 期
- University of Texas - Southwestern Medical Center /ID# 266528, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
招募中1 期
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
招募中1/2 期
- UT Southwestern Medical Center, Dallas
其他城市的 慢性淋巴性白血病 試驗
- Boston, MA31 項研究
- Columbus, OH28 項研究
- Durham, NC27 項研究
- Washington, DC22 項研究
- Seattle, WA20 項研究
- Rochester, MN18 項研究
- New York City, NY18 項研究
- Houston, TX17 項研究
- Baldwin Park, CA16 項研究
- Milwaukee, WI15 項研究
- Chicago, IL14 項研究
- Cincinnati, OH14 項研究
Dallas 的其他研究
- 乳癌55 項研究
- 非小細胞肺癌52 項研究
- 轉移性癌症42 項研究
- 心臟衰竭42 項研究
- 癌症（所有類型）37 項研究
- 前列腺癌36 項研究
- 大腸直腸癌33 項研究
- 肥胖症30 項研究
- 卵巢癌28 項研究
- 肺癌27 項研究
- 膀胱癌27 項研究
- 子宮內膜癌24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。